Sero-Prevalence of Anti-Rubella IgG Antibody (Immunity) Among Pregnant Women in Rogo, a Semi-Urban Community of Kano State, North Western Nigeria

Isma’ila Balarabe¹, Azeez-Akande Oyebanji^2, , Rogo Dahiru Lawal³, Muhammad Yusuf Sabo², Yusuf Ahmed Mustapha², Amadu Magaji⁴, Abubakar Ja’afaru⁵ and Aliyu Mansur²

¹Department of Community Health, School of Health Technology, PMB 11549, Kano-Nigeria

²Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University, PMB 3011, Kano, Nigeria

³Department of Medical Laboratory Science, Faculty of Allied Health Sciences, Bayero University, PMB 3011, Kano, Nigeria

⁴Molecular Biology Unit, Department of Microbiology, Aminu Kano Teaching Hospital, PMB 3452, Kano, Nigeria

⁵National Programme for Stop Transmission of Poliomyelitis, Centre for Disease Control, Kano, Nigeria

Cite this paper:
Isma’ila Balarabe, Azeez-Akande Oyebanji, Rogo Dahiru Lawal, Muhammad Yusuf Sabo, Yusuf Ahmed Mustapha, Amadu Magaji, Abubakar Ja’afaru and Aliyu Mansur. Sero-Prevalence of Anti-Rubella IgG Antibody (Immunity) Among Pregnant Women in Rogo, a Semi-Urban Community of Kano State, North Western Nigeria. American Journal of Infectious Diseases and Microbiology. 2020; 8(2):57-63. doi: 10.12691/ajidm-8-2-3

Abstract

Rubella virus infection (RVI) is, in most cases, a mild disease, but can cause severe defects in developing fetus and new born known as congenital rubella syndrome (CRS) from maternal infection during pregnancy. Rubella remains poorly controlled in many poor-resourced areas (Nigeria inclusive) despite being a vaccine preventable disease. The study aimed to assess the sero-prevalence of anti-rubella IgG antibody (immunity) and level of susceptibility and associated risk factors to rubella virus infection (RVI) among unimmunized pregnant women in a sub-urban setting. It was a hospital-based, cross-sectional descriptive study, conducted in a public general hospital in Rogo, a sub-urban community located in Kano State, Northwest, Nigeria. A total of 174 consented pregnant women [age range, 13-39 years; mean age, 22.3 ± (SD 2.1) years] attending antenatal care (ANC) clinic of a secondary healthcare centre from July to December, 2017 were randomly selected for the study. Information on bio-data, socio-demographic/risk factors and medical history related to previous RVI were obtained via structured questionnaires and hospital records respectively. Blood sample was collected from each study participant and tested for anti-rubella IgG antibody (past exposure) using ELISA technique. Data were analyzed using SPSS statistical software package version 15.0 and Pearson’s Chi-square or Fisher exact test was used for statistical analysis where applicable. A P-value ≤ 0.05 was considered statistically significant. The sero-prevalence of anti-rubella IgG antibody was 93.6% (163 of 174); and rate of susceptibility to RVI among the study population was 6.4% (11 of 174) and were predominant among the study subjects between ages 16 and 25 years in their first trimester of pregnancy. A significant association exists (P<0.05) between parity (P=0.0021) and history of miscarriage or premature birth (P=0.003) and anti-rubella IgG antibody. Similarly, there is an association between sero-negative IgG antibody and parity (P=0.0021) including occupation (subjects in this category were mainly housewives) (P=0.00541) of the study participants. The high rate of rubella exposure by the study participants indicates the presence and high endemicity of rubella infection in the study area, coupled with significant level of susceptibility to RVI by the study subjects. Hence, there is need for adoption of potent rubella vaccine into the routine national immunization programme to limit the spread of RVI and associated complications and clinical sequelae among the populace.

Keywords:
sero-prevalence pregnant women anti-rubella IgG antibody vaccine Rogo-Nigeria

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Center for Disease Control and Prevention. Rubella/German Measles. http://www.cdc.gov/rubella/index.html, 2017. Accessed 18th December, 2019.
[2]	World Health Organization. Rubella Virus https://www.who.int/news-room/fact-sheet/detail/rubella, 2019. Accessed 12th February, 2020.
[3]	Al-Rubai, B., Aboud, M., Hamza, W. Evaluation of Anti-Rubella Antibodies among Childbearing Age Women in Babylon Governorate. Med. J. Babylon 2010; 7:2-6.
[4]	Sreepian, P.M., Sreepian, A. Sero-Prevalence of Rubella Immunity among Women of Childbearing Age in Bangkok Thailand. Southeast J. Trop. Med. Public Health 2018; 49(1): 76-81.
[5]	Abdullahi, U., Sime, S. The Prevalence of Rubella Virus among Children and Adolescents n Adamawa State, Nigeria. J. Adv. Microbiol. 2018; 11(3): 1-6.
[6]	Chopra, S., Mahajan, G. Seroprevalence of Rubella Antibodies among Pregnant Women with a Bad Obstetrics History in Tertiary Care Hospital. Global J. Med. Public. Health 2015; 4 (2): 286-291.
[7]	World Health Organization. Rubella Vaccines: WHO Position Paper Wkly Epidemiol. Rec. 2011; 86: 301-316.
[8]	De Santis, M., Cavaliere, A.F., Straface, G., Caniso, A. Rubella Infection in Pregnancy. Reprod. Toxicol. 2006; 21(4):390-398.
[9]	Brooks, G.F., Carroll, K.C., Butel, J.N., Morse, S.A., Mietzer, T.A. Rubella (German Measles) Virus In: Jawetz, Melnick and Adelberg’s Medical Microbiology, 26th ed. McGraw Hill Lange Comp. USA, 2013 Pp. 607-612.
[10]	Atreya, C.D., Mohan, K.V., Kulkarni, S. Rubella Virus and Birth Defects: Molecular Insights into the Viral Tetratogenesis at the Cellular Level. Clin. Mol. Tetratol. 2004; 70 (7): 431-437.
[11]	Edlich, R.F., Winters, K.L., Long, W.B. Gubler, K.D. Rubella and Congenital Effects (German Measles). J. Long Term Eff. Med. Inplants. 2005; 15(3): 319-328.
[12]	Olajide, O. M., Aminu, M., Randawa, J.A. Seroprevalence of Rubella-Specific IgM and IgG Antibodies among Pregnant Women seen in a Tertiary Hospital in Nigeria. Intern. J. Women’s Health 2015; 7:75-83.
[13]	Frey, T.K. Molecular Biology of Rubella Virus. Adv. Virus Res. 1994; 44: 69-160.
[14]	Junaid, S.A., Akpan, K.J., Olabode, A.O. Sero-Survey of Rubella IgM Antibodies among Children in Jos, Nigeria. Virology J. 2011; 8: 244-248.
[15]	Center for Disease Control and Prevention. Rubella: German Measles, Three-Day Measles. https://www.cdc.gov/rubella/about/index.html. retrieved May 24, 2018.
[16]	Mounerous, S., Malewe, K., Anounou, D. Y., Sami, N., Koffi, A et al. Seroprevalence of Rubella IgG Antibody among Pregnant Women attending Antenatal Clinic in Lome. Togo. Am J. Infect. Dis. Microbiol. 2015; 3:134-136.
[17]	Shaheen, R., Kakru, D.K., Kauser, R., Gaash, B., Hussaini, S.N. Seroprevalence of Rubella Antibodies in Kashmiri Pregnant Women. Indian J. Pract. Doc. 2008; 5: 5-6.
[18]	World Health Organization. Report of a Meeting in Preventing Congenital Rubella Syndrome 2000; https://www.who/int.vaccines documents/docs. retrieved April 14, 2012.
[19]	Oyinloye, S.O., Amama, C.A., Daniel, R., Ajayi, B.B., Lawan, M.A. Seroprevalence Survey of Rubella Antibodies among Pregnant Women in Maiduguri, Borno State, Nigeria. Afr. J. Clin. Exper. Microbiol. 2014; 15: 151-157.
[20]	Gupta, E., Dar, L., Broor, S. Seroprevalence of Rubella in Pregnant Women in Delhi. Indian J. Med. Res. 2006; 123:833-835.
[21]	Palihawadana, P., Wickremasinghe, A. R. Perera, J. Seroprevalence of Rubella Antibodies among Pregnant Females in Sri Lanka, Southeast Asia. J. Trop. Med. Public Health 2003; 34: 398-404.
[22]	Lee, J. Y. Bowden, D.S. Rubella Virus Replicate and Links to Tetragenicity. Clin. Microbiol. Rev. 2000; 13: 571-587.
[23]	Chantler, J., Wolinsky, J.S., Tingle, A. Rubella Virus In: Fields Virology. Kinpe, D.M. Howley, P.M. eds. Lippincott Williams and Wilkins 2001, New York, Pp. 693-991.
[24]	Centers for Disease Control and Prevention. Elimination of Rubella and Congenital Rubella Syndrome-United States, 1969-2004. MMWR Morb. Mortal. Wkly. Rep. 2005; 54 (11): 279-282.
[25]	Ujie, M., Nabae, K., Shobayashi, T. Rubella Outbreak in Japan. Lancet, 2014; 383 (9927): 1460-1461. http://www.the lancet.com/journals/lancet/article/P1150140-6736 (14) 60712-1/fulltext. Retrieved June 14, 2017.
[26]	Centers for Disease Control and Prevention. Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome-Worldwide, 2009. MMWR Morb. Mortal. Wkly Rep. 2010; 59: 1307-1310.
[27]	Onakewhor, J.U., Chiwuzie, J. Seroprevalence Survey of Rubella Infection in Pregnancy at the University of Benin Teaching Hospital, Benin City, Nigeria. Niger J. Clin. Pract. 2011; 14: 140-145.
[28]	Yahaya, H., Ibrahim, A., Muhammad, A.B., Dandawaki, S.M. Seroprevalence Survey of Rubella IgM Antibodies among Pregnant Women in Kano, Nigeria. Int. J. Life Sci. Engr. 2015; 1(2): 56-60.
[29]	Agbede, O.O., Adeyemi, O.O., Olatinwo, A.W.O., Salisu, T. J., Kolawole, O.M. Seroprevalence of Antenatal Rubella in University of Ibadan Teaching Hospital. Open Publ. Health Journal 2011; 4:10-16.
[30]	Adewumi, M.O., Olusanya, R.B., Oladunjoye, B.A., Adeniji, J.A. Rubella IgG Antibody among Nigerian Pregnant Women without Vaccination History. Afr. J. Clin. Exper. Microbiol. 2013; 14(1):40-44.
[31]	Oyenekwe, C.C., Kehinde, Agbeyanhi, T.A., Ofor, U.S., Arinola, O.G. Prevalence of Rubella IgG Antibody in Women of Childbearing Age in Lagos, Nigeria. West Afr. J. Med. 2000; 19(1): 23-26.
[32]	National Population Commission, Nigeria, 2006. http://www.population.gov.nig/index. php/state-population. Retrieved August 16, 2017.
[33]	Lewanga, S.K., Lameshow, S. Sample Size Determination in Health Studies, A Practical Manual, 1991, World Health Organization (WHO), Geneva.
[34]	Sarmukaddam, S.B. Garad, S.G. On Validity of Assumption while Determining Sample Size. Indian J. Comm. Med. 2006; 29(2): 2004-2006.
[35]	Bukbuk, D.N., el-Nafaty, A.U., Obed, J. Y. Prevalence of Rubella-Specific IgG Antibody in Non-Immunized Pregnant Women in Maiduguri, Northwestern Nigeria. Central Europ. Public Health, 2002; 10(1-2): 21-23.
[36]	Noubom, M., Tseyep, D.G., Sama, L.F et al. Seroprevalence of Rubella IgM and IgG Antibodies and Associated Risk Factors among Pregnant Women Attending Antenatal Clinic at Bafoussam Regional Hospital, West Region of Cameroon. J. Trop. Dis. 2018; 6 (4): 1-7.
[37]	Miller, E., Cradock-Watson, J.E., Pollock, T. M. Consequences of Confirmed Maternal Rubella Successive Stages of Pregnancy, Lancet, 1982; 2 (8302): 781-784.
[38]	Chattopadlhyay, S., Biswas, T., Chakraborty, B., Mukherjee, T., Ghosh, P., Mondal, R. Seroprevalence of Rubella Antibodies in Pregnant Women with Bad Obstetrics History attending a Rural Tertiary Care Hospital in West Bengal, India, Intn. J. Med. Dental Sci. 2019; 8(2): 1-5.
[39]	Mueller, C.P., Kremer, J.R., Best, J.M et al. Reducing Global Disease Burden of Measles and Rubella: Report of the WHO Steering Committee on Research Related to Measles and Rubella Vaccines and Vaccination 2005, Vaccine, 2007; 25: 1-9.
[40]	Bangboye, A.E., Afolabi, K.A., Esumeh, F.T., Enweani, I.B. Prevalence of Rubella Antibody in Pregnant Women in Ibadan, Nigeria, West Afr. Med. 2004; 23 (3): 245-248.
[41]	Hamdan, H.Z., Abdelbagi, I.E., Nasser, N.M et al. Seroprevalence of Cytomegalovirus and Rubella among Pregnant Women in Western Sudan, Virol. J. 2011; 8:217-221.
[42]	Fokunang, C.N., Chia, J., Ndumbe, P et al. Clinical Studies on Seroprevalence of Rubella Virus in Pregnant Women of Cameroon Regions. Afr. J. Clin. Exper. Microbiol. 2010; 11: 79-82.
[43]	Mwanbe, B., Mirambo, M.M., Mohana, S.E et al. Seropositivity Rate of Rubella and Associated Factors among Pregnant Women attending Antenatal Care in Mwanza, Tanzania, BMC Preg. Childbirth 2014; 14:95-99.
[44]	Thayyil J., Anitha, M., Biju, G., Bhaskar, R., Kumyil, V. Seroprevalence of Rubella Immunity in Pregnant Women in Kerela, India. Intn. J. Prev. Med. Pub. Health, 2016; 6(4): 189-192.
[45]	Obijimi, T.O., Ajetomobi, A.B., Sule W.F., Oluwayelu, D.O. Prevalence of Rubella Virus Specific Immunoglobulin-G and –M in Pregnant Women attending Two Tertiary Hospitals in Southwestern Nigeria. Afr. J. Clin. Exper. Microbiol. 2013; 14(3): 134-139.
[46]	Muhammad, D.A., Shittu, O., Sadanki, H., Olayinka, A., Kolawole, B., Adejo, D. Prevalence of Rubella IgG Antibodies among Pregnant Women in Zaria. J. Roy. Trop. Med. Hyg. 2010; 2(2): 156-159.
[47]	Adesina, O.A., Adeniyi, A.J., Adeoti, M.O. Rubella IgG Antibody in Women of Childbearing Age in Oyo State. Afr. J. Clin. Exper. Microboil. 2008; 9(2): 78-81.
[48]	Temiat, B. Hussen, S., Shimelis, T. Rubella Virus Infection and Associated Factors among Pregnant Women attending the Antenatal Care Clinics of Public Hospitals in Hawassa City, Southern Ethiopia: A Cross-Sectional Study. BMJ: 2017; 7: 18-24.
[49]	Lambert, N, Strebel, P., Orenstein, W., Jcenogle, J. Rubella, Lancet, 2015; 385 (1): 2297-22307.
[50]	Skendzel, L. Rubella Immunity-Defining the Level of Protective Antibody. Am. J. Clin. Pathol. 1996; 106: 170-174.
[51]	Jubaida, N., Mouldal, M.E.A., Kawsar, N.M. Seroprevalence of Rubella Antibodies in Pregnant Women. J. Armed Forces Med. Coll. Bangladesh, 2011; 17:20-24
[52]	Tahita, M.C. Hubschen, J.M., Tarnagda, Z et al. Rubella Seroprevalence among Pregnant Women in Burkina Faso. BMC Infect. Dis. 2013; 13:164-168.
[53]	Centres for Disease Control and Prevention (CDC). Control and Prevention of Rubella: Evaluation and Management of Suspected Outbreaks, Rubella in Pregnant Women and Surveillance for Congenital Rubella Syndrome. MMWR Recomm. Rep. July 13, 2001; 50(RR12): 1-23.
[54]	Kimberlin, W.D., Rubella Virus. In: Clinical Virology, Richman, D.D., Whitley, J.R., Hayden, G.F. editors, 2nd ed. Washington, D.C.: American Society for Microbiology, 2002; Pp. 1211-1226.